FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313728090> ?p ?o ?g. }

• W4313728090 endingPage "207" @default.
• W4313728090 startingPage "198" @default.
• W4313728090 abstract "Abstract Background In the long-term extension study of the ERASURE and FIXTURE trials, the efficacy of secukinumab (a fully human anti-interleukin-17A monoclonal antibody) was demonstrated to have been maintained through to year 3 of treatment in moderate-to-severe plaque psoriasis. Objectives To assess the efficacy and safety of secukinumab through to year 5 of treatment in moderate-to-severe plaque psoriasis. Methods Responders with ≥ 75% improvement in Psoriasis Area and Severity Index (PASI 75) from two core trials – ERASURE and FIXTURE – were randomized 2 : 1 at year 1 (end of core trials) to either the same dose (300 or 150 mg, continuous treatment) or placebo (treatment withdrawal) every 4 weeks, until year 3 or relapse (&gt; 50% reduction in maximal PASI from core study baseline). Partial responders (achieving PASI 50 but not PASI 75) at year 1 continued at the same dose as in the core trials. At year 3, all patients received open-label secukinumab treatment, with those on secukinumab 300 mg continuing on their dose, while those on secukinumab 150 mg or placebo received secukinumab 150 or 300 mg based on the physician’s discretion. The study is registered on ClinicalTrials.gov with the identifier NCT01544595. Results Most patients randomized to placebo at year 1 relapsed, but the response was rapidly recaptured upon reinitiation of treatment. PASI responses were sustained with secukinumab through to year 5. The PASI responses for the 300 mg responders + partial responders group at year 1 (PASI 75/90/100: 86.8%/72.8%/45.9%) trended downwards until year 3 (PASI 75/90/100: 82.3%/58.4%/32.7%) and then remained stable through year 4 (PASI 75/90/100: 83.3%/60.1%/32.2%) until year 5 (PASI 75/90/100: 81.1%/62.8%/35.1%). Dermatology Life Quality Index showed sustained benefit up to year 5. Absolute PASI responses were maintained throughout the study. The most common adverse events (AEs) were infections and infestations, nasopharyngitis, and upper respiratory tract infections (URTIs). The overall exposure-adjusted incidence rate (EAIR; with 95% confidence interval) for all AEs was 139.9 (130.3–149.9). EAIRs for Crohn's disease and neutropenia were 0.1 (0.0–0.3) and 0.5 (0.3–0.8), respectively. Conclusions The 4-year extension of two pivotal phase III trials demonstrated that secukinumab treatment was effective through to year 5 and improved quality of life in patients with moderate-to-severe plaque psoriasis. The most common AEs were infections and infestations, nasopharyngitis, and URTIs. The safety profile was consistent with that in the secukinumab phase II/III clinical development programme." @default.
• W4313728090 created "2023-01-08" @default.
• W4313728090 creator A5000572878 @default.
• W4313728090 creator A5011569251 @default.
• W4313728090 creator A5019510160 @default.
• W4313728090 creator A5020129995 @default.
• W4313728090 creator A5036110129 @default.
• W4313728090 creator A5042776890 @default.
• W4313728090 creator A5045741722 @default.
• W4313728090 creator A5050331805 @default.
• W4313728090 creator A5061849637 @default.
• W4313728090 creator A5077876525 @default.
• W4313728090 creator A5080223253 @default.
• W4313728090 creator A5082315246 @default.
• W4313728090 creator A5084806976 @default.
• W4313728090 date "2022-10-21" @default.
• W4313728090 modified "2023-10-16" @default.
• W4313728090 title "Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials" @default.
• W4313728090 cites W1957267795 @default.
• W4313728090 cites W1964184432 @default.
• W4313728090 cites W1973354423 @default.
• W4313728090 cites W1977350622 @default.
• W4313728090 cites W2103524303 @default.
• W4313728090 cites W2121623213 @default.
• W4313728090 cites W2129777700 @default.
• W4313728090 cites W2278932593 @default.
• W4313728090 cites W2315900527 @default.
• W4313728090 cites W2359919307 @default.
• W4313728090 cites W2473268399 @default.
• W4313728090 cites W2593781999 @default.
• W4313728090 cites W2755831795 @default.
• W4313728090 cites W2765150986 @default.
• W4313728090 cites W2765883502 @default.
• W4313728090 cites W2769068226 @default.
• W4313728090 cites W2792921896 @default.
• W4313728090 cites W2915037806 @default.
• W4313728090 cites W3000265783 @default.
• W4313728090 cites W3012894524 @default.
• W4313728090 cites W3041193795 @default.
• W4313728090 cites W3042689359 @default.
• W4313728090 cites W3110279795 @default.
• W4313728090 cites W4211077900 @default.
• W4313728090 doi "https://doi.org/10.1093/bjd/ljac040" @default.
• W4313728090 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36763857" @default.
• W4313728090 hasPublicationYear "2022" @default.
• W4313728090 type Work @default.
• W4313728090 citedByCount "4" @default.
• W4313728090 countsByYear W43137280902023 @default.
• W4313728090 crossrefType "journal-article" @default.
• W4313728090 hasAuthorship W4313728090A5000572878 @default.
• W4313728090 hasAuthorship W4313728090A5011569251 @default.
• W4313728090 hasAuthorship W4313728090A5019510160 @default.
• W4313728090 hasAuthorship W4313728090A5020129995 @default.
• W4313728090 hasAuthorship W4313728090A5036110129 @default.
• W4313728090 hasAuthorship W4313728090A5042776890 @default.
• W4313728090 hasAuthorship W4313728090A5045741722 @default.
• W4313728090 hasAuthorship W4313728090A5050331805 @default.
• W4313728090 hasAuthorship W4313728090A5061849637 @default.
• W4313728090 hasAuthorship W4313728090A5077876525 @default.
• W4313728090 hasAuthorship W4313728090A5080223253 @default.
• W4313728090 hasAuthorship W4313728090A5082315246 @default.
• W4313728090 hasAuthorship W4313728090A5084806976 @default.
• W4313728090 hasConcept C126322002 @default.
• W4313728090 hasConcept C142724271 @default.
• W4313728090 hasConcept C16005928 @default.
• W4313728090 hasConcept C168563851 @default.
• W4313728090 hasConcept C204787440 @default.
• W4313728090 hasConcept C27081682 @default.
• W4313728090 hasConcept C2776260265 @default.
• W4313728090 hasConcept C2777011040 @default.
• W4313728090 hasConcept C2779786854 @default.
• W4313728090 hasConcept C2780564577 @default.
• W4313728090 hasConcept C535046627 @default.
• W4313728090 hasConcept C71924100 @default.
• W4313728090 hasConceptScore W4313728090C126322002 @default.
• W4313728090 hasConceptScore W4313728090C142724271 @default.
• W4313728090 hasConceptScore W4313728090C16005928 @default.
• W4313728090 hasConceptScore W4313728090C168563851 @default.
• W4313728090 hasConceptScore W4313728090C204787440 @default.
• W4313728090 hasConceptScore W4313728090C27081682 @default.
• W4313728090 hasConceptScore W4313728090C2776260265 @default.
• W4313728090 hasConceptScore W4313728090C2777011040 @default.
• W4313728090 hasConceptScore W4313728090C2779786854 @default.
• W4313728090 hasConceptScore W4313728090C2780564577 @default.
• W4313728090 hasConceptScore W4313728090C535046627 @default.
• W4313728090 hasConceptScore W4313728090C71924100 @default.
• W4313728090 hasIssue "2" @default.
• W4313728090 hasLocation W43137280901 @default.
• W4313728090 hasLocation W43137280902 @default.
• W4313728090 hasOpenAccess W4313728090 @default.
• W4313728090 hasPrimaryLocation W43137280901 @default.
• W4313728090 hasRelatedWork W2165746902 @default.
• W4313728090 hasRelatedWork W2588369178 @default.
• W4313728090 hasRelatedWork W2621467536 @default.
• W4313728090 hasRelatedWork W2781166685 @default.
• W4313728090 hasRelatedWork W2954778191 @default.
• W4313728090 hasRelatedWork W3022724713 @default.
• W4313728090 hasRelatedWork W3044482886 @default.

• next